Literature DB >> 28852935

SHP2 regulates proliferation and tumorigenicity of glioma stem cells.

Laura Roccograndi1, Zev A Binder1, Logan Zhang1, Nicola Aceto2, Zhuo Zhang3, Mohamed Bentires-Alj4, Ichiro Nakano5, Nadia Dahmane1, Donald M O'Rourke6.   

Abstract

SHP2 is a cytoplasmic protein tyrosine phosphatase (PTPase) involved in multiple signaling pathways and was the first identified proto-oncogene PTPase. Previous work in glioblastoma (GBM) has demonstrated the role of SHP2 PTPase activity in modulating the oncogenic phenotype of adherent GBM cell lines. Mutations in PTPN11, the gene encoding SHP2, have been identified with increasing frequency in GBM. Given the importance of SHP2 in developing neural stem cells, and the importance of glioma stem cells (GSCs) in GBM oncogenesis, we explored the functional role of SHP2 in GSCs. Using paired differentiated and stem cell primary cultures, we investigated the association of SHP2 expression with the tumor stem cell compartment. Proliferation and soft agar assays were used to demonstrate the functional contribution of SHP2 to cell growth and transformation. SHP2 expression correlated with SOX2 expression in GSC lines and was decreased in differentiated cells. Forced differentiation of GSCs by removal of growth factors, as confirmed by loss of SOX2 expression, also resulted in decreased SHP2 expression. Lentiviral-mediated knockdown of SHP2 inhibited proliferation. Finally, growth in soft-agar was similarly inhibited by loss of SHP2 expression. Our results show that SHP2 function is required for cell growth and transformation of the GSC compartment in GBM.

Entities:  

Keywords:  Differentiation; Glioma; PTPN11; SHP2; Stem cells

Mesh:

Substances:

Year:  2017        PMID: 28852935     DOI: 10.1007/s11060-017-2610-x

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  51 in total

1.  Inhibition of EGFR-mediated phosphoinositide-3-OH kinase (PI3-K) signaling and glioblastoma phenotype by signal-regulatory proteins (SIRPs).

Authors:  C J Wu; Z Chen; A Ullrich; M I Greene; D M O'Rourke
Journal:  Oncogene       Date:  2000-08-17       Impact factor: 9.867

2.  Deletion of Shp2 in the brain leads to defective proliferation and differentiation in neural stem cells and early postnatal lethality.

Authors:  Yuehai Ke; Eric E Zhang; Kazuki Hagihara; Dongmei Wu; Yuhong Pang; Rüdiger Klein; Tom Curran; Barbara Ranscht; Gen-Sheng Feng
Journal:  Mol Cell Biol       Date:  2007-07-23       Impact factor: 4.272

3.  Multivariate signaling regulation by SHP2 differentially controls proliferation and therapeutic response in glioma cells.

Authors:  Christopher M Furcht; Janine M Buonato; Nicolas Skuli; Lijoy K Mathew; Andrés R Muñoz Rojas; M Celeste Simon; Matthew J Lazzara
Journal:  J Cell Sci       Date:  2014-06-20       Impact factor: 5.285

4.  Loss of Shp2 in alveoli epithelia induces deregulated surfactant homeostasis, resulting in spontaneous pulmonary fibrosis.

Authors:  Xue Zhang; Yun Zhang; Bo Tao; Li Teng; Yanwei Li; Rui Cao; Qiu Gui; Madong Ye; Xiaozhou Mou; Hongqiang Cheng; Hu Hu; Ren Zhou; Ximei Wu; Qiangmin Xie; Wen Ning; Maode Lai; Huahao Shen; Gen-Sheng Feng; Yuehai Ke
Journal:  FASEB J       Date:  2012-02-23       Impact factor: 5.191

5.  PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase.

Authors:  Rebecca J Chan; Gen-Sheng Feng
Journal:  Blood       Date:  2006-10-19       Impact factor: 22.113

Review 6.  Cancer stem cells in gliomas: identifying and understanding the apex cell in cancer's hierarchy.

Authors:  Monica Venere; Howard A Fine; Peter B Dirks; Jeremy N Rich
Journal:  Glia       Date:  2011-05-05       Impact factor: 7.452

7.  Crosstalk between glioma-initiating cells and endothelial cells drives tumor progression.

Authors:  Hye-Min Jeon; Sung-Hak Kim; Xun Jin; Jong Bae Park; Se Hoon Kim; Kaushal Joshi; Ichiro Nakano; Hyunggee Kim
Journal:  Cancer Res       Date:  2014-06-24       Impact factor: 12.701

8.  SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity.

Authors:  Rosaria Maria Rita Gangemi; Fabrizio Griffero; Daniela Marubbi; Marzia Perera; Maria Cristina Capra; Paolo Malatesta; Gian Luigi Ravetti; Gian Luigi Zona; Antonio Daga; Giorgio Corte
Journal:  Stem Cells       Date:  2009-01       Impact factor: 6.277

Review 9.  Protein-tyrosine phosphatases and cancer.

Authors:  Arne Ostman; Carina Hellberg; Frank D Böhmer
Journal:  Nat Rev Cancer       Date:  2006-04       Impact factor: 60.716

10.  Systems-level interactions between insulin-EGF networks amplify mitogenic signaling.

Authors:  Nikolay Borisov; Edita Aksamitiene; Anatoly Kiyatkin; Stefan Legewie; Jan Berkhout; Thomas Maiwald; Nikolai P Kaimachnikov; Jens Timmer; Jan B Hoek; Boris N Kholodenko
Journal:  Mol Syst Biol       Date:  2009-04-07       Impact factor: 11.429

View more
  17 in total

1.  Myeloid-restricted ablation of Shp2 restrains melanoma growth by amplifying the reciprocal promotion of CXCL9 and IFN-γ production in tumor microenvironment.

Authors:  P Xiao; Y Guo; H Zhang; X Zhang; H Cheng; Q Cao; Y Ke
Journal:  Oncogene       Date:  2018-05-24       Impact factor: 9.867

2.  Next generation sequencing identifies novel potential actionable mutations for grade I meningioma treatment.

Authors:  Francesco Pepe; Pasquale Pisapia; Maria Laura Del Basso de Caro; Floriana Conticelli; Umberto Malapelle; Giancarlo Troncone; Juan Carlos Martinez
Journal:  Histol Histopathol       Date:  2019-12-24       Impact factor: 2.303

3.  Locally secreted BiTEs complement CAR T cells by enhancing killing of antigen heterogeneous solid tumors.

Authors:  Yibo Yin; Jesse L Rodriguez; Nannan Li; Radhika Thokala; MacLean P Nasrallah; Li Hu; Logan Zhang; Jiasi Vicky Zhang; Meghan T Logun; Devneet Kainth; Leila Haddad; Yang Zhao; Tong Wu; Emily X Johns; Yu Long; Hongsheng Liang; Jiping Qi; Xiangtong Zhang; Zev A Binder; Zhiguo Lin; Donald M O'Rourke
Journal:  Mol Ther       Date:  2022-05-14       Impact factor: 12.910

4.  Identification of novel proteins for lacunar stroke by integrating genome-wide association data and human brain proteomes.

Authors:  Chengcheng Zhang; Fengqin Qin; Xiaojing Li; Xiangdong Du; Tao Li
Journal:  BMC Med       Date:  2022-06-23       Impact factor: 11.150

5.  RP58 Represses Transcriptional Programs Linked to Nonneuronal Cell Identity and Glioblastoma Subtypes in Developing Neurons.

Authors:  Chaomei Xiang; Karla K Frietze; Yingtao Bi; Yanwen Li; Valentina Dal Pozzo; Sharmistha Pal; Noah Alexander; Valerie Baubet; Victoria D'Acunto; Christopher E Mason; Ramana V Davuluri; Nadia Dahmane
Journal:  Mol Cell Biol       Date:  2021-06-23       Impact factor: 4.272

6.  Identification of magnetic resonance imaging features for the prediction of molecular profiles of newly diagnosed glioblastoma.

Authors:  Sung Soo Ahn; Chansik An; Yae Won Park; Kyunghwa Han; Jong Hee Chang; Se Hoon Kim; Seung-Koo Lee; Soonmee Cha
Journal:  J Neurooncol       Date:  2021-06-30       Impact factor: 4.130

7.  Data-Driven Computational Modeling Identifies Determinants of Glioblastoma Response to SHP2 Inhibition.

Authors:  Evan K Day; Qing Zhong; Benjamin Purow; Matthew J Lazzara
Journal:  Cancer Res       Date:  2021-02-11       Impact factor: 13.312

Review 8.  SHP2-Mediated Signal Networks in Stem Cell Homeostasis and Dysfunction.

Authors:  Chen Kan; Fan Yang; Siying Wang
Journal:  Stem Cells Int       Date:  2018-06-10       Impact factor: 5.443

Review 9.  Pediatric low-grade glioma in the era of molecular diagnostics.

Authors:  Scott Ryall; Uri Tabori; Cynthia Hawkins
Journal:  Acta Neuropathol Commun       Date:  2020-03-12       Impact factor: 7.801

10.  SHP2 inhibition enhances the anticancer effect of Osimertinib in EGFR T790M mutant lung adenocarcinoma by blocking CXCL8 loop mediated stemness.

Authors:  Leiming Xia; Fan Yang; Xiao Wu; Suzhi Li; Chen Kan; Hong Zheng; Siying Wang
Journal:  Cancer Cell Int       Date:  2021-07-03       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.